Helsinn Healthcare SA And Biovitrum AB Enter A License Agreement For Nordic Marketing Of Aloxi(R)

STOCKHOLM, Sweden--(BUSINESS WIRE)--Feb. 16, 2006--Helsinn Healthcare SA, Switzerland and Biovitrum AB, Sweden announce the signing of an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride) in the Nordic territory.